DOP2011000197A - Derivados de arilciclopropilacetamida utiles como activadores de glucoquinasa - Google Patents

Derivados de arilciclopropilacetamida utiles como activadores de glucoquinasa

Info

Publication number
DOP2011000197A
DOP2011000197A DO2011000197A DO2011000197A DOP2011000197A DO P2011000197 A DOP2011000197 A DO P2011000197A DO 2011000197 A DO2011000197 A DO 2011000197A DO 2011000197 A DO2011000197 A DO 2011000197A DO P2011000197 A DOP2011000197 A DO P2011000197A
Authority
DO
Dominican Republic
Prior art keywords
glucoquinase
arilciclopropilacetamide
activators
derivatives
useful
Prior art date
Application number
DO2011000197A
Other languages
English (en)
Spanish (es)
Inventor
Francisco Javier Agejas-Chicharro
Melendo Ana Belen Bueno
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2011000197A publication Critical patent/DOP2011000197A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DO2011000197A 2008-12-19 2011-06-17 Derivados de arilciclopropilacetamida utiles como activadores de glucoquinasa DOP2011000197A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380341 2008-12-19
US15378109P 2009-02-19 2009-02-19

Publications (1)

Publication Number Publication Date
DOP2011000197A true DOP2011000197A (es) 2011-09-15

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000197A DOP2011000197A (es) 2008-12-19 2011-06-17 Derivados de arilciclopropilacetamida utiles como activadores de glucoquinasa

Country Status (34)

Country Link
US (1) US8063079B2 (cg-RX-API-DMAC10.html)
EP (1) EP2379517B1 (cg-RX-API-DMAC10.html)
JP (1) JP5497064B2 (cg-RX-API-DMAC10.html)
KR (1) KR101290437B1 (cg-RX-API-DMAC10.html)
CN (1) CN102256952B (cg-RX-API-DMAC10.html)
AR (1) AR074470A1 (cg-RX-API-DMAC10.html)
AU (1) AU2009335931B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0923183B1 (cg-RX-API-DMAC10.html)
CA (1) CA2746746C (cg-RX-API-DMAC10.html)
CO (1) CO6382120A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110342A (cg-RX-API-DMAC10.html)
DK (1) DK2379517T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2011000197A (cg-RX-API-DMAC10.html)
EA (1) EA019055B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011150A (cg-RX-API-DMAC10.html)
ES (1) ES2435242T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20130983T1 (cg-RX-API-DMAC10.html)
IL (1) IL213210A (cg-RX-API-DMAC10.html)
JO (1) JO2979B1 (cg-RX-API-DMAC10.html)
MA (1) MA32902B1 (cg-RX-API-DMAC10.html)
MX (1) MX2011006434A (cg-RX-API-DMAC10.html)
MY (1) MY180567A (cg-RX-API-DMAC10.html)
NZ (1) NZ592930A (cg-RX-API-DMAC10.html)
PA (1) PA8851901A1 (cg-RX-API-DMAC10.html)
PE (1) PE20120339A1 (cg-RX-API-DMAC10.html)
PL (1) PL2379517T3 (cg-RX-API-DMAC10.html)
PT (1) PT2379517E (cg-RX-API-DMAC10.html)
SG (1) SG172256A1 (cg-RX-API-DMAC10.html)
SI (1) SI2379517T1 (cg-RX-API-DMAC10.html)
TN (1) TN2011000294A1 (cg-RX-API-DMAC10.html)
TW (1) TWI395748B (cg-RX-API-DMAC10.html)
UA (1) UA104742C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010080333A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201103944B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
WO2015075942A1 (ja) * 2013-11-22 2015-05-28 国立大学法人 東京大学 薬剤送達用のキャリア、コンジュゲートおよびこれらを含んでなる組成物並びにこれらの投与方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282612B1 (en) 2000-05-03 2004-12-29 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
BR0110704A (pt) 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
MXPA02010795A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Activadores de glucocinasa de fenilamida sustituida por para-amino.
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
EA012204B1 (ru) 2004-04-21 2009-08-28 Прозидион Лимитед Три(цикло)замещённые амидные соединения
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
AU2005311269B2 (en) * 2004-12-03 2011-11-10 Transtech Pharma, Inc. Heteroaromatic glucokinase activators
BRPI0612582A2 (pt) 2005-07-01 2010-11-23 Novartis Ag combinação de compostos orgánicos
RU2420525C2 (ru) 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
WO2007017649A1 (en) * 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
CA2626475A1 (en) 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
JP2009514836A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
JP2009544648A (ja) * 2006-07-24 2009-12-17 エフ.ホフマン−ラ ロシュ アーゲー グルコキナーゼ活性化剤としてのピラゾール類
WO2008084872A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物

Also Published As

Publication number Publication date
UA104742C2 (uk) 2014-03-11
EP2379517A1 (en) 2011-10-26
CR20110342A (es) 2011-09-14
EA201170845A1 (ru) 2011-12-30
BRPI0923183A8 (pt) 2017-09-12
KR101290437B1 (ko) 2013-07-29
EP2379517B1 (en) 2013-08-28
IL213210A (en) 2015-03-31
US8063079B2 (en) 2011-11-22
CN102256952B (zh) 2013-12-11
BRPI0923183A2 (pt) 2016-02-16
CA2746746C (en) 2013-09-24
ES2435242T3 (es) 2013-12-17
ECSP11011150A (es) 2011-07-29
TWI395748B (zh) 2013-05-11
JP2012512874A (ja) 2012-06-07
PE20120339A1 (es) 2012-04-16
MY180567A (en) 2020-12-02
PL2379517T3 (pl) 2014-01-31
KR20110086751A (ko) 2011-07-29
ZA201103944B (en) 2012-11-28
WO2010080333A1 (en) 2010-07-15
US20100160395A1 (en) 2010-06-24
EA019055B1 (ru) 2013-12-30
BRPI0923183B1 (pt) 2019-03-19
HRP20130983T1 (hr) 2013-11-22
TW201029999A (en) 2010-08-16
MX2011006434A (es) 2011-07-19
AU2009335931B2 (en) 2012-05-31
MA32902B1 (fr) 2011-12-01
AU2009335931A1 (en) 2011-07-07
NZ592930A (en) 2013-01-25
DK2379517T3 (da) 2013-09-30
SG172256A1 (en) 2011-07-28
IL213210A0 (en) 2011-07-31
PA8851901A1 (es) 2010-07-27
AR074470A1 (es) 2011-01-19
TN2011000294A1 (en) 2012-12-17
CO6382120A2 (es) 2012-02-15
JP5497064B2 (ja) 2014-05-21
CA2746746A1 (en) 2010-07-15
SI2379517T1 (sl) 2013-10-30
CN102256952A (zh) 2011-11-23
PT2379517E (pt) 2013-11-21
JO2979B1 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
DOP2012000006A (es) Agonista de gpr119
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
ECSP11011151A (es) Compuestos purina
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
MX2011005934A (es) Compuestos organicos.
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
DOP2011000009A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
ECSP11011526A (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
CR20120295A (es) Triazolopiridinas
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
ECSP11010760A (es) Derivados de quinoxalindiona
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
BR112015007310A2 (pt) compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
CO6321232A2 (es) Compuesto de tropano como inhibidores de hsp90
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
MX360330B (es) Regimen de administracion para nitrocatecoles.
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.